News Features Funding the Future: How Industry Support for CV Trials Could Evolve Michael O'Riordan December 17, 2020
News Conference News AHA 2020 No Doctor? No Problem: Remote, Pharmacist-Led Intervention Cuts CVD Risk Michael O'Riordan November 19, 2020
News Conference News ESC 2020 Antihypertensives Cut CV Events Across BP Levels, Regardless of Prior CVD: BPLTTC Shelley Wood August 31, 2020
News Features COVID-19’s Enduring Impact on the Heart? Some Clues and Predictions Shelley Wood July 20, 2020
News Daily News FOURIER Surveys Reassure About Cognitive Safety of Evolocumab Todd Neale May 06, 2020
News Conference News ACC 2020 Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events Michael O'Riordan April 02, 2020
News Daily News Earlier, Longer Interventions Proposed for Optimal Population LDL Cholesterol Yael L. Maxwell January 28, 2020
News Features ‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry Michael O'Riordan January 10, 2020